Analysts Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.60

Shares of Immunic, Inc. (NASDAQ:IMUX - Get Free Report) have earned a consensus recommendation of "Buy" from the eight analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $11.60.

A number of research analysts have issued reports on the company. HC Wainwright reiterated a "buy" rating and set a $10.00 price target on shares of Immunic in a research report on Thursday, May 1st. D. Boral Capital restated a "buy" rating and set a $10.00 price objective on shares of Immunic in a research note on Wednesday, June 25th. William Blair reissued an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. Finally, B. Riley reissued a "buy" rating and set a $5.00 target price (down previously from $6.00) on shares of Immunic in a research note on Friday, May 23rd.

Hedge Funds Weigh In On Immunic

Large investors have recently bought and sold shares of the stock. Invesco Ltd. bought a new position in shares of Immunic during the 4th quarter valued at about $37,000. Barclays PLC bought a new position in shares of Immunic during the 4th quarter valued at about $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock valued at $205,000 after purchasing an additional 96,894 shares in the last quarter. Jane Street Group LLC boosted its position in shares of Immunic by 279.3% during the 1st quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock valued at $226,000 after purchasing an additional 152,726 shares in the last quarter. Finally, Bridgeway Capital Management LLC boosted its position in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after purchasing an additional 22,200 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Trading Down 2.8%

Immunic stock traded down $0.02 during midday trading on Friday, hitting $0.81. The stock had a trading volume of 663,130 shares, compared to its average volume of 979,124. The business has a fifty day moving average price of $0.85 and a 200 day moving average price of $0.98. Immunic has a 12 month low of $0.56 and a 12 month high of $2.11. The stock has a market cap of $77.21 million, a P/E ratio of -0.66 and a beta of 1.49.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). On average, equities analysts anticipate that Immunic will post -0.94 EPS for the current fiscal year.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.